J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…

Read More

KFF Standards and Practices

KFF Standards and Practices Published: January 13, 2025 Introduction This document’s intent is to serve as a roadmap that sets expectations clearly for how we work together and behave in a principled and ethical manner. It applies equally to all KFF staff across the board as well as for any freelancers doing work under our…More

Read More

Prioritize Provider Data for Seamless M&A Success

Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for navigating today’s increasingly frequent healthcare consolidations. The post Prioritize Provider Data for Seamless M&A Success appeared first on MedCity News.

Read More